Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma with extramedullary disease: Comparative outcomes and evolving strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

RAReema AnjumUAUmmul AsfeenBBBhaswanth Bollu

Discussion

Loading...

Member takes

Overview

Systematic review shows anti-BCMA CAR T-cell therapy yields high initial response rates in EMD, suggesting room for dual-targeted strategies.

Key Points

  • The review aims to synthesize clinical outcomes and biological insights of anti-BCMA CAR T-cell therapy in EMD patients with multiple myeloma.
  • Systematic search of major databases from inception to July 2025
  • Included studies with adults having relapsed/refractory myeloma and EMD
  • Two reviewers screened records and extracted data on CAR construct and outcomes
  • High initial response rates to anti-BCMA CAR-T therapy were observed in EMD patients
  • Comparative analysis showed lower progression-free survival and overall survival in EMD cohorts
  • Emerging dual-targeted strategies showed promising efficacy and tolerability

Cite This Study

Anjum et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc19https://doi.org/10.1182/blood-2025-7608
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti‐<scp>BCMA CAR</scp> T‐cell‐based therapy2024 · 23 citations
  2. 2Clinical outcomes and microenvironment profiling of relapsed/refractory extramedullary disease of multiple myeloma patients with anti-BCMA CAR T cell-based therapy2024 · 1 citations
  3. 3Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease2026 · 1 citations
  4. 4BCMA-directed CAR-T cell therapy in relapsed/refractory multiple myeloma: efficacy, safety, survival, and future directions - A systematic review and meta-analysis.2026 · 1 citations
  5. 5BCMA-CART therapy in 29 cases of relapsed or refractory multiple myeloma:a retrospective study2025